Aetna · Clinical coverage policy

Aetna Prostate Cancer Screening coverage criteria

Aetna covers PSA screening and annual digital rectal exam as preventive prostate cancer screening for average-risk men age 45+ and high-risk men age 40+ (African-American men or those with a family history), plus diagnostic PSA testing for men with signs/symptoms or follow-up of known prostate cancer; routine screening at age 75+ is covered only if life expectancy is at least 10 years. A long list of alternative biomarkers and assays (e.g., PCA3, four-kallikrein panel, Stockholm3, TMPRSS2:ERG, selenium measurement) is considered experimental and investigational for screening.

Policy CPB 0521 · Effective · Verify against the current Aetna policy before submitting — view source policy.

Payer

Aetna

Policy

CPB 0521

Prior auth

Confirm

Effective

January 1, 2026

This page reflects the coverage criteria captured from Aetna policy CPB 0521 and may not include every criterion, exception, or code — verify the complete bulletin before submitting.

What this means for the claim

The covered path, the next step to get it approved, and the specific way it denies — built only from this policy.

When does Aetna cover Prostate Cancer Screening (CPT 84152), and what gets it denied?

Path
Aetna covers PSA screening and annual digital rectal exam as preventive prostate cancer screening for average-risk men age 45+ and high-risk men age 40+ (African-American men or those with a family history), plus diagnostic PSA testing for men with signs/symptoms or follow-up of known prostate cancer; routine screening at age 75+ is covered only if life expectancy is at least 10 years. A long list of alternative biomarkers and assays (e.g., PCA3, four-kallikrein panel, Stockholm3, TMPRSS2:ERG, selenium measurement) is considered experimental and investigational for screening. Coverage criteria include: PSA (prostate-specific antigen) screening is considered medically necessary as a preventive service for men 45 years of age and older who are considered average-risk for prostate cancer; PSA screening is considered medically necessary for men 40 years of age and older who are considered at high-risk for prostate cancer (high-risk = African-American men OR men with a family history of prostate cancer); Annual PSA screening is considered medically necessary when used for routine screening in men with previously elevated PSAs or signs/symptoms of disease; PSA testing is considered medically necessary for men of all ages with signs or symptoms of prostate cancer; PSA testing is considered medically necessary for follow-up of men with prostate cancer; Annual digital rectal examination (DRE) is considered medically necessary; Routine prostate cancer screening for members 75 years of age or older is considered medically necessary ONLY when life expectancy is greater than or equal to 10 years (otherwise considered not medically necessary); Medically necessary diagnostic PSA testing is covered regardless of whether the member has preventive service benefits (note: some plans exclude coverage of preventive services; check benefit plan descriptions). Applies to 5 codes: 84152, 84153, 84154, G0102, G0103.
Action
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source.
Trap
Policy exclusions and limitations: Routine prostate cancer screening for members 75 years of age or older is considered not medically necessary UNLESS life expectancy is greater than or equal to 10 years; Selenium measurement (in blood or tissues such as toenail clippings) to assess prostate cancer risk is considered experimental, investigational, and unproven because it has no proven value for this indication; The following are considered experimental, investigational, and unproven for prostate cancer screening because they have no proven value for this indication: +RNAinsight for ProstateNext; Alpha-methylacyl coenzyme A racemase (AMACR) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Analysis of prostatic fluid electrolyte composition (e.g., citrate, zinc) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Apifiny non-PSA blood test (Armune BioScience) for prostate cancer screening - experimental, investigational, and unproven (no proven value); BRAF mutations for prostate cancer screening - experimental, investigational, and unproven (no proven value); Early prostate cancer antigen for prostate cancer screening - experimental, investigational, and unproven (no proven value); Endoglin for prostate cancer screening - experimental, investigational, and unproven (no proven value); EpiSwitch Prostate Screening Test for prostate cancer screening - experimental, investigational, and unproven (no proven value); E twenty-six (ETS) gene fusions for prostate cancer screening - experimental, investigational, and unproven (no proven value); Four-kallikrein panel (total PSA, free PSA, intact PSA, human kallikrein-2) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Genetic-based screening for prostate cancer screening - experimental, investigational, and unproven (no proven value); Human glandular kallikrein 2 (hK2/KLK2) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Interleukin-6 for prostate cancer screening - experimental, investigational, and unproven (no proven value); MicroRNAs (in prostatic fluid/tissue) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Neutrophil gelatinase-associated lipocalin (NGAL) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Prostate cancer gene 3 (PCA3) for prostate cancer screening - experimental, investigational, and unproven (no proven value); ProstateNext for prostate cancer screening - experimental, investigational, and unproven (no proven value); Stockholm3 for prostate cancer screening - experimental, investigational, and unproven (no proven value); TMPRSS2:ERG gene fusion for prostate cancer screening - experimental, investigational, and unproven (no proven value); Transforming growth factor-beta 1 for prostate cancer screening - experimental, investigational, and unproven (no proven value). Claims may be denied when the requested service falls under these. Some of these are conditional (note the stated exceptions) — confirm specifics against the bulletin.

Source: Aetna CPB 0521 — Prostate Cancer Screening

Coverage criteria

  • PSA (prostate-specific antigen) screening is considered medically necessary as a preventive service for men 45 years of age and older who are considered average-risk for prostate cancer
  • PSA screening is considered medically necessary for men 40 years of age and older who are considered at high-risk for prostate cancer (high-risk = African-American men OR men with a family history of prostate cancer)
  • Annual PSA screening is considered medically necessary when used for routine screening in men with previously elevated PSAs or signs/symptoms of disease
  • PSA testing is considered medically necessary for men of all ages with signs or symptoms of prostate cancer
  • PSA testing is considered medically necessary for follow-up of men with prostate cancer
  • Annual digital rectal examination (DRE) is considered medically necessary
  • Routine prostate cancer screening for members 75 years of age or older is considered medically necessary ONLY when life expectancy is greater than or equal to 10 years (otherwise considered not medically necessary)
  • Medically necessary diagnostic PSA testing is covered regardless of whether the member has preventive service benefits (note: some plans exclude coverage of preventive services; check benefit plan descriptions)

Covered codes

Codes listed in this Aetna policy. Check each one's prior-authorization verdict and Medicare rate:

Frequently asked questions

When does Aetna cover Prostate Cancer Screening (CPT 84152), and what gets it denied?
Aetna covers PSA screening and annual digital rectal exam as preventive prostate cancer screening for average-risk men age 45+ and high-risk men age 40+ (African-American men or those with a family history), plus diagnostic PSA testing for men with signs/symptoms or follow-up of known prostate cancer; routine screening at age 75+ is covered only if life expectancy is at least 10 years. A long list of alternative biomarkers and assays (e.g., PCA3, four-kallikrein panel, Stockholm3, TMPRSS2:ERG, selenium measurement) is considered experimental and investigational for screening. Coverage criteria include: PSA (prostate-specific antigen) screening is considered medically necessary as a preventive service for men 45 years of age and older who are considered average-risk for prostate cancer; PSA screening is considered medically necessary for men 40 years of age and older who are considered at high-risk for prostate cancer (high-risk = African-American men OR men with a family history of prostate cancer); Annual PSA screening is considered medically necessary when used for routine screening in men with previously elevated PSAs or signs/symptoms of disease; PSA testing is considered medically necessary for men of all ages with signs or symptoms of prostate cancer; PSA testing is considered medically necessary for follow-up of men with prostate cancer; Annual digital rectal examination (DRE) is considered medically necessary; Routine prostate cancer screening for members 75 years of age or older is considered medically necessary ONLY when life expectancy is greater than or equal to 10 years (otherwise considered not medically necessary); Medically necessary diagnostic PSA testing is covered regardless of whether the member has preventive service benefits (note: some plans exclude coverage of preventive services; check benefit plan descriptions). Applies to 5 codes: 84152, 84153, 84154, G0102, G0103. Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source. Policy exclusions and limitations: Routine prostate cancer screening for members 75 years of age or older is considered not medically necessary UNLESS life expectancy is greater than or equal to 10 years; Selenium measurement (in blood or tissues such as toenail clippings) to assess prostate cancer risk is considered experimental, investigational, and unproven because it has no proven value for this indication; The following are considered experimental, investigational, and unproven for prostate cancer screening because they have no proven value for this indication: +RNAinsight for ProstateNext; Alpha-methylacyl coenzyme A racemase (AMACR) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Analysis of prostatic fluid electrolyte composition (e.g., citrate, zinc) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Apifiny non-PSA blood test (Armune BioScience) for prostate cancer screening - experimental, investigational, and unproven (no proven value); BRAF mutations for prostate cancer screening - experimental, investigational, and unproven (no proven value); Early prostate cancer antigen for prostate cancer screening - experimental, investigational, and unproven (no proven value); Endoglin for prostate cancer screening - experimental, investigational, and unproven (no proven value); EpiSwitch Prostate Screening Test for prostate cancer screening - experimental, investigational, and unproven (no proven value); E twenty-six (ETS) gene fusions for prostate cancer screening - experimental, investigational, and unproven (no proven value); Four-kallikrein panel (total PSA, free PSA, intact PSA, human kallikrein-2) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Genetic-based screening for prostate cancer screening - experimental, investigational, and unproven (no proven value); Human glandular kallikrein 2 (hK2/KLK2) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Interleukin-6 for prostate cancer screening - experimental, investigational, and unproven (no proven value); MicroRNAs (in prostatic fluid/tissue) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Neutrophil gelatinase-associated lipocalin (NGAL) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Prostate cancer gene 3 (PCA3) for prostate cancer screening - experimental, investigational, and unproven (no proven value); ProstateNext for prostate cancer screening - experimental, investigational, and unproven (no proven value); Stockholm3 for prostate cancer screening - experimental, investigational, and unproven (no proven value); TMPRSS2:ERG gene fusion for prostate cancer screening - experimental, investigational, and unproven (no proven value); Transforming growth factor-beta 1 for prostate cancer screening - experimental, investigational, and unproven (no proven value). Claims may be denied when the requested service falls under these. Some of these are conditional (note the stated exceptions) — confirm specifics against the bulletin.
Does Aetna require prior authorization for Prostate Cancer Screening?
Confirm prior-authorization status with Aetna before scheduling — it is code- and plan-specific, and this policy is not an exact authorization source.
What does Aetna exclude for Prostate Cancer Screening?
Policy exclusions and limitations: Routine prostate cancer screening for members 75 years of age or older is considered not medically necessary UNLESS life expectancy is greater than or equal to 10 years; Selenium measurement (in blood or tissues such as toenail clippings) to assess prostate cancer risk is considered experimental, investigational, and unproven because it has no proven value for this indication; The following are considered experimental, investigational, and unproven for prostate cancer screening because they have no proven value for this indication: +RNAinsight for ProstateNext; Alpha-methylacyl coenzyme A racemase (AMACR) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Analysis of prostatic fluid electrolyte composition (e.g., citrate, zinc) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Apifiny non-PSA blood test (Armune BioScience) for prostate cancer screening - experimental, investigational, and unproven (no proven value); BRAF mutations for prostate cancer screening - experimental, investigational, and unproven (no proven value); Early prostate cancer antigen for prostate cancer screening - experimental, investigational, and unproven (no proven value); Endoglin for prostate cancer screening - experimental, investigational, and unproven (no proven value); EpiSwitch Prostate Screening Test for prostate cancer screening - experimental, investigational, and unproven (no proven value); E twenty-six (ETS) gene fusions for prostate cancer screening - experimental, investigational, and unproven (no proven value); Four-kallikrein panel (total PSA, free PSA, intact PSA, human kallikrein-2) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Genetic-based screening for prostate cancer screening - experimental, investigational, and unproven (no proven value); Human glandular kallikrein 2 (hK2/KLK2) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Interleukin-6 for prostate cancer screening - experimental, investigational, and unproven (no proven value); MicroRNAs (in prostatic fluid/tissue) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Neutrophil gelatinase-associated lipocalin (NGAL) for prostate cancer screening - experimental, investigational, and unproven (no proven value); Prostate cancer gene 3 (PCA3) for prostate cancer screening - experimental, investigational, and unproven (no proven value); ProstateNext for prostate cancer screening - experimental, investigational, and unproven (no proven value); Stockholm3 for prostate cancer screening - experimental, investigational, and unproven (no proven value); TMPRSS2:ERG gene fusion for prostate cancer screening - experimental, investigational, and unproven (no proven value); Transforming growth factor-beta 1 for prostate cancer screening - experimental, investigational, and unproven (no proven value). Claims may be denied when the requested service falls under these. Some of these are conditional (note the stated exceptions) — confirm specifics against the bulletin.

Source

Aetna CPB 0521 — Prostate Cancer Screening

Related

Need this Aetna approval drafted?

Ask D3 builds the documentation checklist and a ready-to-send request from this policy's criteria — cited, free, no signup.

Ask D3 Free

Coverage disclaimer

This page summarizes Aetna clinical-coverage criteria extracted from policy CPB 0521 for educational purposes. Coverage policies change and vary by individual plan. Always verify against Aetna's current policy before performing a procedure or submitting a claim. d3rx is not responsible for claim denials or reimbursement issues.